Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 19;23(20):12554.
doi: 10.3390/ijms232012554.

Human Papillomavirus 16 E2 as an Apoptosis-Inducing Protein for Cancer Treatment: A Systematic Review

Affiliations

Human Papillomavirus 16 E2 as an Apoptosis-Inducing Protein for Cancer Treatment: A Systematic Review

Dinah Farhanah Jamal et al. Int J Mol Sci. .

Abstract

Human papillomavirus type 16 (HPV-16) is a well-known etiological factor for cervical and oropharyngeal cancers. The E2 protein, the product of an early-transcribed gene in HPV-16, is postulated to cause the death of cancerous cells via p53-dependent and p53-independent pathways. The main aim of the present systematic review was to study the HPV 16-E2 protein as an apoptosis-inducer agent. A thorough search of MEDLINE/PubMed, Science Direct, Scopus, and EBSCOhost databases was conducted for relevant studies on HPV AND apoptosis OR cell death where HPV 16-E2 was involved. The search identified 967 publications. Eleven records dated from 1 January 1997 to 16 February 2022 were found to meet the inclusion criteria and were eligible for data extraction and inclusion. All studies concluded that HPV 16-E2 was able to induce cell death in transfected cells. E2 proteins from the high-risk HPV-16 were able to induce apoptosis through different apoptotic pathways depending on the location of the expressed gene. However, the mechanism was still unclear, and further studies are warranted.

Keywords: E2 protein; HPV 16; apoptosis; cell death; human papillomavirus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA used in the methods in the study. Total of records were 967 and a final of 11 studies were included.

Similar articles

Cited by

References

    1. Estimated Number of New Cases in 2020, Worldwide, Females, All Ages. [(accessed on 20 August 2021)]. Available online: https://gco.iarc.fr/
    1. Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer. Lancet. 2019;393:169–182. doi: 10.1016/S0140-6736(18)32470-X. - DOI - PubMed
    1. Bruni L.B.R.L., Barrionuevo-Rosas L., Albero G., Aldea M., Serrano B., Valencia S., Brotons M., Mena M., Cosano R., Muñoz J., et al. Human Papillomavirus and Related Diseases in the World. Institut Català d’Oncologia; Barcelona, Spain: 2019. Summary Report.
    1. Robadi I.A., Pharaon M., Ducatman B.S. The Importance of High-Risk Human Papillomavirus Types Other Than 16 and 18 in Cervical Neoplasia. Arch. Pathol. Lab. Med. 2018;142:693–695. doi: 10.5858/arpa.2017-0563-RA. - DOI - PubMed
    1. de Sanjosé S., Brotons M., Pavón M.A. The natural history of human papillomavirus infection. Best. Pract. Res. Clin. Obstet. Gynaecol. 2018;47:2–13. doi: 10.1016/j.bpobgyn.2017.08.015. - DOI - PubMed

Publication types

MeSH terms

Substances